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ABSTRACT
Introduction: Translational research networks are
a deliberate strategy to bridge the gulf between
biomedical research and clinical practice through
interdisciplinary collaboration, supportive funding and
infrastructure. The social network approach examines
how the structure of the network and players who hold
important positions within it constrain or enable
function. This information can be used to guide
network management and optimise its operations. The
aim of this study was to describe the structure of
a translational cancer research network (TCRN) in
Australia over its ﬁrst year, identify the key players
within the network and explore these players’
opportunities and constraints in maximising important
network collaborations.
Methods and analysis: This study deploys a mixed-
method longitudinal design using social network
analysis augmented by interviews and review of TCRN
documents. The study will use network documents and
interviews with governing body members to explore
the broader context into which the network is
embedded as well as the perceptions and expectations
of members. Of particular interest are the attitudes and
perceptions of clinicians compared with those of
researchers. A co-authorship network will be
constructed of TCRN members using journal and
citation databases to assess the success of past
pre-network collaborations. Two whole network social
network surveys will be administered 12 months apart
and parameters such as density, clustering, centrality
and betweenness centrality computed and compared
using UCINET and Netdraw. Key players will be
identiﬁed and interviewed to understand the speciﬁc
activities, barriers and enablers they face in that role.
Ethics and dissemination: Ethics approvals were
obtained from the University of New South Wales,
South Eastern Sydney Northern Sector Local Health
Network and Calvary Health Care Sydney. Results will
be discussed with members of the TCRN, submitted to
relevant journals and presented as oral presentations
to clinicians, researchers and policymakers.
INTRODUCTION
Translational research networks
Notable even among other dynamic ﬁelds
contributing to the scientiﬁc knowledge
explosion, biomedical research has greatly
increased in output and complexity with the
sequencing of the human genome and
advances in sophisticated new technologies.
1 2
As a result, increasingly specialised language,
concepts and understandings have deepened
the gulf between scientists and clinicians.
Translational research is a deliberate strategy
that seeks to transform biomedical research
‘at the bench’ into clinical practice ‘at the
bedside’ through interdisciplinary collabora-
tion and a range of supportive infrastructure,
funding and staff.
3e5
There are two distinct phases of trans-
lational research referred to as T1 and T2 by
the Institute of Medicine’s Clinical Round
Table, each with unique goals, settings and
participants.
6 T1 refers to the interface
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Open Access Protocolbetween the laboratory and the clinical setting, striving
to ﬁnd how new knowledge of disease mechanisms can
be developed into clinically relevant understandings,
and diagnostic and treatment regimes to be trialled in
humans. T2 seeks the translation of new clinically proven
knowledge of disease processes, diagnostic or treatment
techniques into routine clinical practice and health
decision making.
67Others have suggested T3: practice-
based research,
8 where the evidence from clinical trials
on carefully selected patients is translated into guide-
lines for complex patients seen routinely in practice.
Barriers to successful translation include structural,
ﬁnancial, cognitive and cultural factors. Structural
barriers include the pressures of clinical service delivery,
which have left many hospital or practice-based clini-
cians with insufﬁcient time for research.
6 9e12 The
unreliability of funding for translational research
compounds this problem,
10 13 as does the lack of
a recognised career path for translational researchers or
clinicianescientists.
12 13
Cognitive barriers include the need to understand
unique research design in order to translate research
generated in the highly controlled laboratory environ-
ment into the relatively chaotic and complex clinical
environment.
8 12 This may incorporate the use of
experts such as biostatisticians to interpret results and
information technology specialists to design and run
more complex computer algorithms for integrated
analyses.
14 Furthermore, research carried out in the
clinical setting requires the negotiation of a mineﬁeld of
legal and regulatory requirements.
13 15 Lack of stand-
ardisation of clinical trial protocols, data recording and
evidence thresholds are also cited as barriers.
61 41 6
Inability to access results from previous trials or research
programmes, especially those that have not reached
publication, also hinders translation.
10 14 16
Most signiﬁcant is the difference between the ‘two
cultures’
10: the contrasting paradigms, culture, expertise
and language of basic science and clinical practice that
need to be understood to prevent miscommunications,
mismatched expectations and team conﬂict.
91 01 31 7The
divide is so signiﬁcant that translational researchers may
variously be seen as interpreters,
13 liaisons
9 or conﬂict
managers,
18 in order to facilitate the collaboration.
Professional networks that bring together biomedical
researchers and clinicians are believed to be an ideal
vehicle to address the challenges of translational
research allowing sharing of expertise, infrastructure
and knowledge. In the USA, the National Centre for
Advancing Translational Sciences has been established,
complemented by the provision of dedicated grants for
translational research (Clinical and Translational
Science Awards) as well as a raft of recommendations
and infrastructure support from the National Institutes
of Health.
4 51 21 5The UK has invested £450 million over
5 years to establish translational research centres
including an Informatics Initiative.
71 2Australia also has
invested in translational research initiatives such as
Academic Health Sciences Centres,
19 and the funding of
four new Translational Cancer Research Centres by the
Cancer Institute of New South Wales.
20
The social network approach
It is not clear how far funding incentives and streamlined
infrastructure will take us in addressing the challenges
inherent in translational research. An alternative
approach is to look at translational collaborative initiatives
through a social network lens. Social networks are deﬁned
as sets of people (actors) with relationships, ties or
interactions between them.
21 Translational research
groupings are social networks with ties of communication
and collaborative interactions between members. The
focus of social network studies is the network’s structure
and how this relates to its function, for example, its efﬁ-
ciency of communication ﬂows and resilience to change.
Network structure provides the context for individuals’
actions including the constraining and enabling factors
that affect their behaviour.
22 Certain positions within the
network are highly inﬂuential and individuals who hold
these positions are referred to key players.
A social network approach can inform management of
the network and suggest ways in which to optimise its
function.
23 Moreover, attention to the role of key players
in such networks may identify opportunities and barriers
to improved network function and enable targeted
interventions.
18 24 The aim of this study was to describe
the structure of a translational cancer research network
(TCRN) over the ﬁrst year of its operation, identify the
key players within the network and explore these players’
opportunities and constraints in maximising important
collaborative network functions.
The setting is a newly formed TCRN in New South
Wales, Australia. The TCRN’s stated aim is to develop
a ‘sustainable translational research engine’ by providing
leadership, co-ordination and infrastructure to a collab-
oration of 67 members made up of a variety of clinicians
based primarily in hospitals, and university-based
biomedical and health services researchers. The network
has members from six different campuses and repre-
sentation from a range of domains such as basic science,
pathology, primary health, oncology and radiology. The
TCRN ofﬁcially commenced in July 2011. A project
manager was appointed in September 2011, and actual
project negotiations between members began in January
2012. Data collection for this study commenced in early
2012 at a time when there had been little ofﬁcial TCRN
contact between most members. However, arising from
a competitive grant process, the TCRN necessarily
brought together a core of members who were known to
one another and who had previously collaborated on
research projects.
Collaborative networks
Translational research networks seek to set up conditions
under which research can be optimally initiated and
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Network structure and key players in a translational research networkspread. Grouping members from different disciplines,
sites and specialties, aiming to maximise knowledge
transfer, ensuring co-ordination of activities and easy
access to resources is a common theme in the trans-
lational research literature.
3 471 01 21 41 62 5 e27 Collabo-
rative networks are, of course, found across many other
ﬁelds and in many contexts such as commercial, political
and community, and there is a large body of literature
considering various aspects of network structure and
their mediating effects.
The customary tool for empirical measurement of
network structure is social network analysis (SNA). While
attribute data (eg, gender, age or years of experience)
are usually collected in SNA, it is relational data that
deﬁne the actual network structure.
28 Ties need to be
tightly deﬁned as different relationships produce
different networks. For example, the network deﬁned by
friendship may well be different from the network
deﬁned by reporting structure. This study will consider
a number of different networks and characteristics:
actual relationships such as past collaborations, people
participants have worked with or know socially, as well as
‘cognitive ties’ or perceptions,
29 such as intended future
collaborations, or people they consider powerful or
well-connected.
Some network parameters measured by SNA, used to
describe the network’s functioning, have been shown to
affect network outcomes. These include the overall
density and cohesion of network members, members’
homophily and tendency to form discrete clusters within
networks, the strength of ties between them, the gaps or
structural holes between these clusters and the presence
or absence of key players. The next section contains
a discussion of these factors in terms of the research
hypotheses they generate.
Density and cohesion
The density of the network is the number of links
between members expressed as a proportion of the
maximum possible number of links.
28 Network density is
a measure therefore of how connected members are.
Densely linked networks are more efﬁcient at diffusing
information to all their members when compared with
sparsely linked groups.
30 Dense networks are also resil-
ient to the loss of individual actors as there are enough
alternate linkages to cover the loss. High density also
prevents bottlenecks in advice-seeking or information
networks. Cummings and Cross,
31 in their study of 182
workgroups in a global business organisation, found that
when actors had to go through their manager to get
information or advice from an appropriate third party,
productivity and efﬁciency suffered.
The TCRN is embedded in a pre-existing and complex
interorganisational network of long-standing research
and teaching arrangements as well as self-initiated
collaborative research. TCRN activities and funded
projects do not displace existing and ongoing
research such as National Health and Medical Research
Councilefunded projects. At its inception, the TCRN
was already a collaborative effort with core group
members who prepared and submitted the proposal to
the funding body. Past collaborative ties and knowledge
of a broad range of clinicians and researchers therefore
deﬁne the starting point of the network and give a base
line for growth in linkages of members and new
collaborations over time.
Hypothesis 1: The TCRN’s precursor collaboration
network has a high density index.
Other network relationships considered are members
they have worked with (but not collaborated with in
translational research) and members they know socially
(from outside of the work setting), referred to here as
the work network and social network, respectively. It is
expected that these ties will not be as frequent, and
therefore, these networks will not be as dense as the
precursor collaboration network.
Hypothesis 2: The TCRN’s precursor collaboration
network has a higher density than either the work
network or the social network.
Homophily and clusters
Discrete areas of high density in a network are termed as
clusters, and the gaps between them can slow or impede
the ﬂow of information or other resources within
a network. Identifying the basis of clustering can be an
important step in improving network function.
32 The
two cultures of researchers and clinicians, discussed
above,
10 are the most obvious factors distinguishing
members in a translational research network. Members
will be asked to identify themselves as primarily ‘clini-
cian,’ ‘researcher’ or the hybrid ‘clinicianeresearcher.’
Hypothesis 3: Members of the TCRN cluster primarily
around the ‘two cultures’ of academic research and
clinical practice.
Strong as this factor may be, other factors may also be
relevant. Homophily is typically associated with clus-
tering and is deﬁned by Rogers as “the extent to which
two or more individuals who interact are similar in
certain attributes.”
30 Attributes found to contribute to
homophily apart from occupation include age, gender
and level of education (see review by Brass et al
33).
Network analyses of health teams have shown strong
clustering around individual professions. Creswick and
colleagues
34e36 employed SNA on a renal ward and an
emergency department of a large metropolitan hospital
in Australia. They were able to show that across social
advice-seeking and medication advice-seeking networks,
there was clustering along professional lines: nursing,
medical and allied health staff. West and Barron
37
surveyed senior nurses and physician leaders in an acute
care hospital in the UK. They found strong evidence to
support their conjecture that clinicians’ occupational
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network based on ties with people with whom they
discussed important professional matters, the clustering
was strongest among their sample of doctors compared
with the nurses, and homophily was also found on the
basis of age, gender and level of experience. Similarly,
studies of interdisciplinary research collaborations in
university settings show clustering within research
groups and disciplines.
38 39
Clustering can also be associated with organisational
structures. Actors employed doing the same tasks or in
a similar hierarchical role have more reasons and
opportunities to interact with each other. Cott
40 showed
two contrasting clusters in her analysis of decision-
making teams in residential aged care: senior nurses and
medical staff (those who ‘decide’) and junior and night
staff nurses (those who ‘carry out’). Geographic prox-
imity (eg, working in the same hospital)
37 and temporal
alignment (eg, working the night shift or previously
working together in the same place)
40 also allow
enhanced opportunities to interact and can result in
clusters for certain types of interaction.
Attributes expected to contribute to homophily and
clustering in the TCRN are specialty (meaning here the
particular subarea of oncology research such as molec-
ular biology, palliative care or radiotherapy), geographic
location, seniority, profession and member’s key tasks
(such as direct patient care, supervision of students or
laboratory work). It is noted that some of these factors
overlap and differentiation of exact factors will be difﬁ-
cult, for example, key tasks and profession or seniority.
However, it is expected that after the researchere
clinician divide, the next most inﬂuential attribute will
be specialty, based on the observation that wards, clinical
services and research laboratories tend to be grouped
this way.
Hypothesis 4: Clustering within the TCRN is also associ-
ated with specialty, and to a lesser extent, geographic
location, seniority, profession and key tasks.
Strength of ties
Relationship ties can be weighted to reﬂect their
strength, usually by assessing the frequency or intensity
of contact.
41 Strong ties have been associated with
transfer of complex and tacit knowledge,
42 and work
teams’ efﬁciency and stability over time.
43 Strong ties are
also associated with trust, another determinant of
network success.
44e46 Weak, in contrast to strong, ties
imply less frequent contact and less invested time in the
relationship.
47 Strong ties have been associated with
negative outcomes such as forming exclusive cliques that
can impede communication within the network. TCRN
members will be asked to weight the various relation-
ships in their past collaboration, work and social
networks as one of four strengths, from very weak to very
strong. A ﬁfth category, “I don’t know this person at all”
is used for the members not nominated. Again, given the
antecedents of the TCRN, it is expected that past
collaboration ties will be strong and work and social
networks weak.
Hypothesis 5: The TCRN’s past collaboration network has
a high proportion of strong ties.
Hypothesis 6: The TCRN’s work and social networks have
a high proportion of weak ties.
Strong ties between members can also isolate the
whole network from the broader industry and restrict
the innovation that comes from access to new sources of
information.
41 48 It is now recognised that a combination
of strong and weak ties are needed to maximise
productivity,
23 with a number of studies showing varying
combinations of the two across a range of contexts (eg,
see Jippes et al
49and Ahuja
50).
Key players
SNA has allowed the identiﬁcation of a range of actors
that Borgatti terms key players
51: actors who have
important roles within the network and are deﬁned by
their position within the overall structure. The two most
common key players, central actors and bridging actors,
are referred to by a confusingly wide range of names,
some synonymous, others emphasising different aspects
of the role across diverse settings. Actors who occupy
central highly connected positions in the network are
termed variously as central actors (eg, see Creswick
et al
36, Hawe and Ghali
52 and McAneney et al
53), opinion
leaders (eg, see Valente
54, Valente and Pumpuang
55,
Gifford et al
56 and Ankem
57), hubs (eg, see Buchanan
58
and Watts and Strogatz
59) or connectors.
60 Earlier
sociometric studies called these people communication
‘stars,’ meaning actors who are chosen as friends by the
most people
61 or who are the individuals most
approached for advice in a work setting.
62 Central actors
are able to co-ordinate activities and direct resources
most efﬁciently due to their knowledge of and access to
the most members in the network.
47 63 Prestige and
power are also often associated with central actors due to
their unique position of control and access. Central
actors who are said to have an opinion leading role have
been shown to help dissemination of innovations
49 56 64
and to lead clinical quality and safety initiatives.
65
Central actors in the TCRN are likely to be members of
the core foundational group that initiated the funding
proposal and so are also likely to be senior members of
their specialty or profession. The clearest pattern of
centrality is likely to be seen in the past collaboration
network. It is expected that other members will perceive
these central actors as ‘powerful’ or ‘inﬂuential’
individuals.
Hypothesis 7: Actors with high centrality in the past
collaboration network are also perceived as powerful or
inﬂuential actors by other members.
While clusters can show how people are grouped
generally, a more precise deﬁnition of the gaps between
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structural hole exists between two actors who are said to
be non-redundant: that is between two actors who
themselves are not connected.
47 Contacts are said to be
redundant to the extent that they lead to the same people
and so provide the same information or opportunities.
Non-redundancy therefore offers opportunities and
information that can be accessed uniquely by the actor
spanning the structural hole. Access to novel information
is part of the mechanism behind generating ‘good ideas’
or innovations according to Burt,
66 67 an important
function of TCRNs. The inclusion of many different
domains of cancer expertise in the TCRN is a deliberate
strategy to facilitate this bridging of the gaps to produce
innovative research ideas. Players who actually do the
bridging will be brokering that potential innovation and
are of particular interest to this study.
Key players who span structural holes have been given
a wide variety of names, the commonest being
bridges,
47 68 boundary spanners or riders,
69 or
brokers.
70e72 Gould and Fernadez,
71 looking at what
they call transaction networks, divided the role of the
boundary spanner into ﬁve categories each reﬂecting
a unique role, motivation or context. For example,
gatekeepers are actors who bridge the structural hole
between their cluster and an outside cluster, controlling
what information passes into or out of their cluster.
These categories have been expanded by Shi and
colleagues
72 to eight categories to include a hierarchical
dimension. Cross and Prusak
70 divide the roles differ-
ently again: central connectors, peripheral specialists,
boundary spanners and information brokers.
A focus of this study is to understand the role and
associated activities of key players within translational
research networks. Gray,
18 considering the role of
a transdisciplinary researcher, conceptualises the
bridging role as one of conﬂict resolution. The impor-
tance of understanding concepts and language from
both sides of the structural hole is seen as the key to
facilitating collaboration across the divide.
Bridges within the TCRN will be those members who
form a link between existing clusters. Since it is
hypothesised that the main basis for clusters or structural
holes is the researchereclinician divide, members who
specialise in clinical research and who have a so-called
‘foot in each camp’ are the most likely bridges.
Hypothesis 8: Actors identiﬁed as being bridges across
structural holes in the TCRN are more likely to deﬁne
themselves as clinicianeresearchers.
Some TCRN members are the nominated representa-
tives of an outside work group or service that may
provide information, expertise or resources relevant to
TCRN activities. Others are planning to be the link
between the TCRN and their colleagues, workplace or
association to disseminate TCRN ﬁndings most effec-
tively. Since the TCRN is embedded in the complex
interorganisational structure of the NSW health system,
all members are expected to be members of some
common outside groups. However, the gap between the
TCRN and other non-TCRN groups can be considered
a structural hole if the TCRN member spanning the gap
is the only link. Such links to outside groups has been
strongly linked to innovative output. Shan and
colleagues,
73 considering the gap between biotech-
nology companies as a structural hole, found that the
number of bridging ties that the company had with
other companies was positively related to its innovation
output. Ahuja
50 found the same relationship in the
pharmaceutical industry, but only up to a point; beyond
which increasing the number of structural holes led to
a decrease in innovative output.
The broader reach of the TCRN will be assessed by
asking members to name outside groups to which they
plan to disseminate TCRN ﬁndings and activities, or
whom they represent (such as a service or owner of
a particular resource). Members who are involved with
many outside groups are often perceived as ‘well-
connected’ and can be labelled ‘cosmopolites’ (from the
adjective cosmopolitan) and may be approached as
a go-between or liaison, another bridging role.
Hypothesis 9: Actors identiﬁed as being bridges from the
TCRN to relevant outside groups are perceived as
well-connected members.
METHOD/DESIGN
This study is a mixed-method longitudinal study of
a TCRN designed in seven phases. It uses documentary
evidence, interviews, two online social network surveys
12 months apart and citation databases to examine the
broader context into which the TCRN is embedded, the
unique features of the network and how it changes in
structure over the initial 12 month period, as well as
focusing on the speciﬁc activities and perceptions of its
key players.
Phase 1
A systematic review of the empirical peer-reviewed liter-
ature on socialeprofessional networks and key network
players was undertaken to inform the design of the
study (Long JC, Cunningham FC, Braithwaite J. Brokers
in socialeprofessional networks: a systematic review,
2012, in preparation).
Phase 2
In this phase, the context of the network will be
described. The research manager will be interviewed and
documents produced by the TCRN will be reviewed. This
will provide an understanding of the network’s respon-
sibilities towards the funding body, their formal objec-
tives and outcomes and the rationale behind
administrative decisions such as the composition of
support staff, choice of initial membership and invest-
ment in infrastructure. Demographic information about
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profession will be sourced from the network’s
documentation.
Phase 3
This will consist of semistructured interviews with the 13
members of the Governing Council. Questions seek to
elicit information about the wider translational research
context into which the TCRN is being introduced.
Participants will be asked to give information and opin-
ions on the human and social capital they bring to the
network, their perceptions of their role within
the network, of how they will measure success, and of the
challenges to producing satisfactory outcomes. Partici-
pants will also be asked to speculate on the basis of any
clusters that might be revealed through SNA. Differ-
ences in network expectations and perceptions between
hospital-based and university-based participants will be
of particular interest. Participants will also be asked
about past collaboration with other TCRN members.
These responses will help to inform design of the social
network survey.
Phase 4
This phase will start with the piloting of the online social
network survey on 10 members of equivalent clinical or
research experience in another network. Feedback from
the pilot will be used to reﬁne and clarify the survey
before all members of the TCRN are invited to complete
it with each member receiving a link to the secure survey
site via personal email. The survey is a whole network
survey;
74 75 that is, all members are being surveyed rather
than a sample of members. Therefore to maximise the
response rate, two follow-up reminders will be emailed to
non-respondents at 2 and 4 weeks.
The survey is divided into two sections. The ﬁrst section
collects demographic information (not able to be
sourced from TCRN documents), which is hypothesised
to be associated with clustering: key tasks, seniority, past
or present places of work or tertiary study and member-
ship in other networks. As some members have a clinical
role as well as a research role, it is anticipated that the
concept of the ‘two cultures’ or clinician or researcher
may be unclear. Members will therefore be asked whether
they identify more with the title clinician, researcher or
clinicaleresearcher and their answer compared with
other demographic information they give.
The members’ perceptions of the TCRN and their role
within it will be explored with a series of questions.
Check box answers will be used to collect information on
members’ method of joining the network (self-initiated,
by invitation or required by a superior) and motives for
joining (answers reﬂecting an altruistic and patient-
centred attitude, an organisation-centred or profession-
centred attitude or a more opportunistic approach).
Respondents will be asked if their role in the network
includes representing their work group, their place of
work or their profession and will be given an opportunity
to name the group represented. Likewise, respondents
who indicate that part of their role is the dissemination
of TCRN ﬁndings and activities will be asked to nomi-
nate the groups they are likely to target and the number
of people they could potentially reach. As well as role
perceptions these questions give an indication of the
potential reach of the TCRN into a wider setting.
Members will be asked about challenges facing the
success of the network answering ﬁrst in free text and
then choosing from a list of barriers and facilitators
drawn from the literature and phase 3 interviews.
The second section of the survey contains a roster of
members’ names, grouped by primary place of work and
asks two sets of questions that seek to ascertain the
number and strength of interactions between network
members before the TCRN formed, and interactions that
formed or were intending to be formed as a direct result
of the TCRN. Respondents will be asked to nominate
members with whom they had previously collaborated,
worked or knew socially (three parallel questions).
Choosing one of four relationship categories will indicate
the strength of each of these nominated relationships:
weak (no longer in contact), medium (infrequent or
superﬁcial contact), strong (frequent or purposeful
contact) or long-standing (long-term, stable relationship
irrespective of frequency of contact). The second set of
social network questions will ask about intended future
collaborations as part of the TCRN and perceptions of
powerful, inﬂuential and well-connected members.
Phase 5
A co-authorship network will be constructed where links
in the network are deﬁned by whether members have
authored a paper with another member. This will give an
indication of the success of previous collaborations
among the TCRN members. Members’ names will be
searched for individually within Scopus and Web of
Science citation databases from 1980 till April 2012 and
articles downloaded into an Endnote library (an elec-
tronic referencing programme). Grey literature will be
included as well as peer reviewed journal articles (but
will be able to be differentiated in the network). After
removing duplicates, co-authors will be identiﬁed and
each collaboration recorded as a tie between those
members. Published output will be compared to the
collaborations nominated in the social network survey as
a measure of their success.
Phase 6
In this phase, up to ﬁve key players identiﬁed from phase
4 will be interviewed. Members’ roles will be explored,
in-depth: their perceptions of how the network functions
and their role in it, including speciﬁc details on their
activities and experience of constraining and facilitating
factors for those activities.
Phase 7
Finally, in phase 7 the online social network survey will
be re-administered to all members of the network
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time, the number of network members will have at least
doubled.
ANALYSES
Interviews will be recorded, transcribed and analysed
with the assistance of NVivo9, a software package.
Themes will be coded by two independent reviewers and
ﬁnalised using an iterative process of discussion.
Social networks (with weighted relations), current
and future collaboration networks and the co-author-
ship networks will be analysed using UCINET V.6 soft-
ware,
76 and NetDraw will be used to map the networks
graphically.
77 Whole network parameters such as
density, mean path length and centrality will be
computed. Changes between the network at time 1 and
time 2 will be evaluated. Network graphics will be used
to visually explore the networks. Demographic data will
be used to determine the basis of clustering. Central
actors will be identiﬁed by mean degree (number of ties
as a proportion of the number of actors), global
centrality (the most connected actors within the
network)
78 and betweenness centrality (the extent to
which an actor lies between actors that would not
otherwise be connected).
78 Bridges that span structural
holes will identiﬁed by betweenness centrality
78
and bridging.
68 Individual actors and sites will all be
de-identiﬁed for presentation.
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